GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Cyclically Adjusted PB Ratio

DARE (Dare Bioscience) Cyclically Adjusted PB Ratio : 0.07 (As of May. 30, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Cyclically Adjusted PB Ratio?

As of today (2025-05-30), Dare Bioscience's current share price is $2.88. Dare Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $43.64. Dare Bioscience's Cyclically Adjusted PB Ratio for today is 0.07.

The historical rank and industry rank for Dare Bioscience's Cyclically Adjusted PB Ratio or its related term are showing as below:

DARE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.07   Max: 0.39
Current: 0.07

During the past years, Dare Bioscience's highest Cyclically Adjusted PB Ratio was 0.39. The lowest was 0.04. And the median was 0.07.

DARE's Cyclically Adjusted PB Ratio is ranked better than
91.64% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs DARE: 0.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Dare Bioscience's adjusted book value per share data for the three months ended in Mar. 2025 was $-1.081. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $43.64 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dare Bioscience Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Dare Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Cyclically Adjusted PB Ratio Chart

Dare Bioscience Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.24 0.06 0.06

Dare Bioscience Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.05 0.06 0.07

Competitive Comparison of Dare Bioscience's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Dare Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dare Bioscience's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's Cyclically Adjusted PB Ratio falls into.


;
;

Dare Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Dare Bioscience's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.88/43.64
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Dare Bioscience's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.081/134.9266*134.9266
=-1.081

Current CPI (Mar. 2025) = 134.9266.

Dare Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201506 299.132 100.684 400.867
201509 257.206 100.392 345.686
201512 213.785 99.792 289.053
201603 157.820 100.470 211.944
201606 113.333 101.688 150.378
201609 72.890 101.861 96.551
201612 -2.950 101.863 -3.908
201703 31.988 102.862 41.959
201706 16.773 103.349 21.898
201709 44.498 104.136 57.655
201712 26.375 104.011 34.215
201803 16.618 105.290 21.296
201806 12.834 106.317 16.288
201809 10.067 106.507 12.753
201812 7.066 105.998 8.994
201903 3.971 107.251 4.996
201906 3.657 108.070 4.566
201909 1.302 108.329 1.622
201912 0.269 108.420 0.335
202003 1.562 108.902 1.935
202006 0.131 108.767 0.163
202009 -0.495 109.815 -0.608
202012 -0.332 109.897 -0.408
202103 0.826 111.754 0.997
202106 1.619 114.631 1.906
202109 4.996 115.734 5.824
202112 5.540 117.630 6.355
202203 4.414 121.301 4.910
202206 4.674 125.017 5.044
202209 3.727 125.227 4.016
202212 1.572 125.222 1.694
202303 0.692 127.348 0.733
202306 -0.377 128.729 -0.395
202309 -0.279 129.860 -0.290
202312 -0.606 129.419 -0.632
202403 -1.312 131.776 -1.343
202406 0.313 132.554 0.319
202409 -0.174 133.029 -0.176
202412 -0.691 133.157 -0.700
202503 -1.081 134.927 -1.081

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dare Bioscience  (NAS:DARE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Dare Bioscience Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dare Bioscience Business Description

Traded in Other Exchanges
N/A
Address
3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Executives
Sophia Nnenna Ononye-onyia director 1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson director, officer: Chef Executive Officer 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair officer: Chief Strategy Officer C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley director 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz director 1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman director C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert officer: Chief Financial Officer C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof officer: SVP, Chief Scientific Officer C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz officer: SVP, Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle director VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal officer: VP, General Counsel C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill officer: Principal Accounting Officer 15 GREENBRIAR CIRCLE, ANDOVER MA 01810